Free Trial
NASDAQ:OCS

Oculis (OCS) Stock Price, News & Analysis

Oculis logo
$17.61 -0.03 (-0.17%)
As of 08/1/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Oculis Stock (NASDAQ:OCS)

Key Stats

Today's Range
$17.52
$17.90
50-Day Range
$17.50
$19.92
52-Week Range
$10.79
$23.08
Volume
7,983 shs
Average Volume
13,854 shs
Market Capitalization
$772.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.33
Consensus Rating
Buy

Company Overview

Oculis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

OCS MarketRank™: 

Oculis scored higher than 54% of companies evaluated by MarketBeat, and ranked 513th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oculis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Oculis has only been the subject of 1 research reports in the past 90 days.

  • Read more about Oculis' stock forecast and price target.
  • Earnings Growth

    Earnings for Oculis are expected to grow in the coming year, from ($2.09) to ($2.05) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oculis is -6.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oculis is -6.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oculis has a P/B Ratio of 9.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Oculis' valuation and earnings.
  • Percentage of Shares Shorted

    0.06% of the float of Oculis has been sold short.
  • Short Interest Ratio / Days to Cover

    Oculis has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Oculis has recently decreased by 60.57%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Oculis does not currently pay a dividend.

  • Dividend Growth

    Oculis does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.06% of the float of Oculis has been sold short.
  • Short Interest Ratio / Days to Cover

    Oculis has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Oculis has recently decreased by 60.57%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Oculis has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Oculis this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Oculis insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    Only 22.30% of the stock of Oculis is held by institutions.

  • Read more about Oculis' insider trading history.
Receive OCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oculis and its competitors with MarketBeat's FREE daily newsletter.

OCS Stock News Headlines

This Crypto Is Set to Explode in January
This Could Be the Most Important Crypto Law in History While the world celebrates Bitcoin becoming 2025’s top-performing asset, smart hedge funds are accumulating elsewhere. During the upcoming Crypto Hedge Fund Summit, you'll discover exactly which coins they’ve loaded up on before this historic vote.
Oculis Upsized Loan Facility to Access up to CHF 100 million
Oculis Upsized Loan Facility to Access up to CHF 100 million
OCS - Oculis Holding AG Executives - Morningstar
Oculis Holding AG (OCS) - Yahoo Finance
See More Headlines

OCS Stock Analysis - Frequently Asked Questions

Oculis' stock was trading at $17.00 on January 1st, 2025. Since then, OCS shares have increased by 4.1% and is now trading at $17.70.

Oculis Holding AG (NASDAQ:OCS) released its quarterly earnings data on Thursday, May, 8th. The company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.26. The business had revenue of $0.32 million for the quarter, compared to the consensus estimate of $0.22 million. Oculis had a negative net margin of 13,788.70% and a negative trailing twelve-month return on equity of 92.95%.

Oculis' top institutional investors include Compagnie Lombard Odier SCmA (0.22%).

Shares of OCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oculis investors own include SoFi Technologies (SOFI), Meta Platforms (META), Bitdeer Technologies Group (BTDR), Purpose Bitcoin ETF (BTCC.B), Booz Allen Hamilton (BAH), Broadcom (AVGO) and Atara Biotherapeutics (ATRA).

Company Calendar

Last Earnings
5/08/2025
Today
8/02/2025
Next Earnings (Estimated)
8/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OCS
CIK
1953530
Fax
N/A
Employees
2
Year Founded
N/A

Price Target and Rating

High Price Target
$41.00
Low Price Target
$32.00
Potential Upside/Downside
+99.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$97.43 million
Net Margins
-13,788.70%
Pretax Margin
-13,815.93%
Return on Equity
-92.95%
Return on Assets
-70.03%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.79
Quick Ratio
4.79

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.91 per share
Price / Book
9.27

Miscellaneous

Outstanding Shares
43,662,000
Free Float
N/A
Market Cap
$772.82 million
Optionable
Not Optionable
Beta
0.28
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:OCS) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners